Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
5.64
-0.38 (-6.40%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Kalaris Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Market Capitalization | 129 | 158 | - | - | - |
| Enterprise Value | 13 | 82 | - | - | - |
| Last Close Price | 5.63 | 8.44 | - | - | - |
| PB Ratio | 1.64 | 2.00 | - | - | - |
| P/TBV Ratio | 1.64 | 2.00 | - | - | - |
| Debt / Equity Ratio | 0.02 | 0.02 | -0.39 | - | -0.61 |
| Net Debt / Equity Ratio | -1.48 | -1.48 | -0.36 | 5.20 | -0.04 |
| Net Debt / EBITDA Ratio | 2.53 | 2.53 | - | - | - |
| Net Debt / FCF Ratio | 3.02 | 3.02 | -0.88 | 0.22 | -0.02 |
| Quick Ratio | 12.15 | 12.15 | 0.07 | 0.80 | 0.54 |
| Current Ratio | 12.23 | 12.23 | 0.11 | 0.85 | 0.69 |
| Return on Equity (ROE) | -308.10% | -308.10% | - | - | - |
| Return on Assets (ROA) | -45.11% | -45.11% | -681.04% | -232.72% | - |
| Return on Capital Employed (ROCE) | -41.20% | -41.20% | 279.00% | 2210.80% | 781.60% |
| Earnings Yield | -33.62% | -27.52% | - | - | - |
| FCF Yield | -29.85% | -24.44% | - | - | - |
| Buyback Yield / Dilution | -1042.87% | -1042.87% | 77.99% | -36.56% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.